MEG
CRL icon

Millstone Evans Group’s Charles River Laboratories CRL Stock Holding History

Millstone Evans Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.76K Hold
16
– – ﹤0.01% 725
2025
Q4 		$3.19K Hold
16
– – ﹤0.01% 705
2025
Q3 		$2.5K Buy
+16
New +$2.54K ﹤0.01% 717

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millstone Evans Group's CRL Position: Q1 2026 in Review

Millstone Evans Group held its Charles River Laboratories (CRL) position steady in Q1 2026 at 16 shares worth $2.76K. The position accounts for ﹤0.01% of the portfolio, ranked #725.

Millstone Evans Group first reported a position in CRL in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.19K in Q4 2025. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Millstone Evans Group held 16 shares of Charles River Laboratories worth $2.76K as of Q1 2026.
  • Millstone Evans Group left its Charles River Laboratories share count unchanged in Q1 2026.
  • Charles River Laboratories made up ﹤0.01% of Millstone Evans Group's portfolio in Q1 2026, its #725 holding.
  • Millstone Evans Group first reported a position in Charles River Laboratories in Q3 2025 and has held it in 3 quarters since.
  • Millstone Evans Group's Charles River Laboratories position peaked at $3.19K in Q4 2025.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Millstone Evans Group's 13F filing for Q1 2026, filed 30 Apr 2026.